newsfilter
← Latest News
GlobeNewswire·

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...